Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus

D Ellison, K Gatter, A Heryet, M Esiri

Abstract

Aims: To test the hypothesis that fragments of platelet thrombi and vascular endothelium are incorporated into the walls of small cerebral vessels in systemic lupus erythematosus (SLE).

Methods: Six varied necropsy cases of central nervous system (CNS) SLE and 15 controls were studied. The controls were selected to represent a wide range of diseases in which the cerebral circulation is compromised. Tissue sections were stained by standard histochemical and immunocytochemical methods, the latter using antibodies to platelet membrane glycoprotein IIIa (CD61), and vascular endothelium (CD31).

Results: In four of six cases of CNS SLE characterised by small vessel hyalinisation and thickening, fragments of platelet membrane were found in the walls of small cortical and meningeal vessels. Similar findings were not evident in two other SLE cases that were characterised by relatively short clinical histories and an acute vasculitis. One control case of severe polyarteritis nodosa showed platelet fragment deposition in arteries larger than the vessels so affected in SLE.

Conclusions: Previous studies have suggested that neuropsychiatric symptoms in SLE may be related to repeated episodes of vasculitis in small cerebral vessels that are triggered by antiphospholipid antibodies. Concurrent thrombus formation might facilitate the incorporation of platelet fragments into small vessel walls. This process contributes to the thickening and irregularity of small vessels, a major feature of longstanding cases of CNS SLE.

Methods

The clinical details of the six cases of CNS SLE that we examined are summarised in table 1. All six patients fulfilled the American Rheumatism Association’s revised 1982 criteria for SLE.10 Fifteen control cases were selected for comparison. Three of these patients had normal brains, having died from myocardial infarction. The other cases were chosen because the cerebral vasculature had in some way been compromised. Two patients had had a single episode of cerebral infarction. Atherosclerosis and giant cell arteritis were the causes of multiple infarcts in two further cases. There were two patients who had polyarteritis nodosa with involvement of cerebral vessels. One of these had a particularly severe and widespread arteritis with fibrinoid necrosis. Five cases of CNS infection were included. Three were bacterial and two were fungal in origin. A reactive arteritis could be found in four of five of these cases; and small areas of infarction could be found in three of five cases. Fungal invasion of the vessels was seen in the example of Aspergillus meningitis.

Histological sections were cut from paraffin wax embedded, formalin fixed tissue. Routine histochemical methods (haematoxylin and eosin, cresyl violet and luxol fast blue, elastic van Gieson, Martius scarlet blue) were used. Immunocytochemistry was performed using the APAAP method as described previously.11 The primary antibodies were: Y2/51 which recognise CD61, platelet membrane glycoprotein IIIa12; and JC70 which recognise CD31, a membrane bound glycoprotein which occurs in vascular endothelium.13 Adjacent tissue sections were used for immunocytochemistry because of the capacity of JC70 occasionally to label platelets.13 A section to which serum, but not antibody, had been applied was included as a control.

Neuropsychiatric symptoms are common in systemic lupus erythematosus (SLE), occurring in up to 75% of cases.1 2 Central nervous system (CNS) pathology is found in about half the cases studied at necropsy, including some without CNS symptoms.3 The principal findings in two major reviews of the pathology of CNS SLE were vasculopathy and microinfarction.4 5 The pathogenesis of these lesions is unclear, but antiphospholipid and antiendothelial antibodies present in the serum of some patients with SLE have been implicated in cerebrovascular damage.6 7 Transient inflammatory reactions involving such antibodies may, in combination with the action of antineuronal antibodies, underlie the fluctuating neuropsychiatric symptoms that occur during the course of SLE.8 9 The incorporation of platelet fragments from thrombi into vessel walls or the disruption of vascular endothelium might reasonably be expected during these inflammatory episodes, and may contribute to the cerebral vasculopathy in chronic cases. To investigate this possibility, we studied the vascular pathology in six cases of CNS SLE, using conventional histochemical methods and immunocytochemical methods with two antibodies. One of these detects platelet membranes (Y2/51; classified CD61), and the other labels vascular endothelium (JC70; classified CD31).
Table 1 Details of patients with central nervous system SLE

<table>
<thead>
<tr>
<th>Case No</th>
<th>Age</th>
<th>Sex</th>
<th>Duration of SLE symptoms</th>
<th>CNS symptoms/signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>41</td>
<td>F</td>
<td>4 years</td>
<td>Transverse myelitis</td>
</tr>
<tr>
<td>2</td>
<td>47</td>
<td>F</td>
<td>20 years</td>
<td>Neuropsychiatric symptoms, limb paraesthesiae, cranial nerve palsies</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>F</td>
<td>9 years</td>
<td>Neuropsychiatric symptoms, bilateral pyramidal signs, cerebellar signs</td>
</tr>
<tr>
<td>4</td>
<td>53</td>
<td>M</td>
<td>1 year</td>
<td>Limb paraesthesiae, cerebellar signs</td>
</tr>
<tr>
<td>5</td>
<td>54</td>
<td>F</td>
<td>17 years</td>
<td>Neuropsychiatric symptoms, epilepsy, tetraplegia, chorea</td>
</tr>
<tr>
<td>6</td>
<td>66</td>
<td>F</td>
<td>6 years</td>
<td>Dementia, epilepsy, chorea</td>
</tr>
</tbody>
</table>

Table 2 Neuropathological features of six cases with CNS SLE

<table>
<thead>
<tr>
<th>Case No</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain weight (g)</td>
<td>1320</td>
<td>1220</td>
<td>1400</td>
<td>1580</td>
<td>970</td>
<td>1230</td>
</tr>
<tr>
<td>Infarction*</td>
<td>o</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>o</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Vasculitis†</td>
<td>o</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>o</td>
<td>o</td>
</tr>
<tr>
<td>Small vessel vasculopathy‡</td>
<td>+</td>
<td>+</td>
<td>o</td>
<td>o</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Endothelial proliferation</td>
<td>o</td>
<td>+</td>
<td>o</td>
<td>o</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Perivascular haemorrhage</td>
<td>o</td>
<td>+</td>
<td>o</td>
<td>o</td>
<td>o</td>
<td>o</td>
</tr>
<tr>
<td>Y2/51 staining</td>
<td>+</td>
<td>+</td>
<td>o</td>
<td>o</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

*macroinfarction or microinfarction
†acute or subacute
‡hyaline thickening and eosinophilia.

Results

This small series of patients with CNS SLE demonstrated a wide spectrum of clinical and neuropathological features (tables 1 and 2). For example, one patient presented shortly before death with his first CNS symptoms while another had had the neuropsychiatric symptoms that are typical of SLE over 17 years. The range of pathology is exemplified by the findings in these two cases. The brain of the first patient weighed 1580 g, which reflected the presence of oedema, petechial haemorrhages, and infarction secondary to acute vasculitis (fig 1); while the brain of the second patient weighed 970 g, which reflected gross cerebral atrophy secondary to extensive laminar necrosis of the cortex. The laminar necrosis was present in a distribution that suggested numerous foci of ischaemia; and cystic infarction was present in many other areas of this brain. Recent or old infarction in five of six brains from patients with SLE was multifocal and ranged widely in size.

Vascular abnormalities were evident in all six SLE patients. A vasculopathy that manifests as hyaline thickening, eosinophilia, and sometimes endothelial proliferation of small vessels was seen in four of six cases (table 2). Deposits of material that were positively labelled by antibody Y2/51 (CD61) were found within the walls of a small proportion of thickened vessels in each of these cases (figs 2A and B). The deposits were nearly always found in meningeal and cortical vessels with a diameter of less than 100 μm, and up to 10 foci might be found in a typical section from the frontal pole. On adjacent sections from two of these four cases, JC70 (CD31) labelled material was very occasionally found at the same sites as the Y2/51 positive material (fig 3). However, other Y2/51 deposits in these cases were not matched by JC70 staining on adjacent tissue sections; and the latter antibody elsewhere delineated normal endothelium alone. Intramural fibrin was rarely found in the thickened small vessels of the four cases with vasculopathy (fig 4).

No intramural Y2/51 deposits were seen in two of six cases of SLE. A feature of both these cases was acute vasculitis. In one, an acute inflammatory infiltrate of polymorph neutrophils disrupted small vessels and spread out into the surrounding necrotic tissue. Thrombosis and perivascular haemorrhages were associated findings. Perivascular haemorrhage was a prominent feature in the other case where inflammatory cells congregated preferentially in venules. Vasculopathy was absent in both of these brains. When intramural Y2/51 positive material was associated with vasculitis
Discussion

The six cases of CNS SLE are characterised by a wide spectrum of neuropathological features. This spectrum encompasses all the cerebrovascular pathology reported in two studies of the brains of patients with CNS SLE. These studies concluded that while acute vasculitis was rare in a large postmortem series of SLE cases, “vasculopathy” was a common finding. Vasculopathy includes hyaline thickening and eosinophilia of the vessel wall, fibrinoid degeneration, and endothelial proliferation. It may be accompanied by thrombosis.

Vasculopathy of this type was seen in four of six cases of SLE in the present study. Intramural platelet fragments detected by antibody Y2/51 were seen in small (<100 μm diameter), thickened vessels in the same four cases. We could find no intramural deposits of Y2/51 material in the two other SLE cases. An acute and devastating brain stem and cerebellar vasculitis was the first CNS lesion for one of these patients (case 4; tables 1 and 2), occurring one year after his first symptoms of SLE. No feature of a cerebral vasculopathy was found in this brain or that of the other patient (case 3; tables 1 and 2) who had had the symptoms of CNS SLE for five months before her death. These patients did not have a long history of CNS symptoms in contrast to the four with vasculopathy. Vasculopathy may be the hallmark of repeated attacks of CNS SLE over several years, and the incorporation of platelet membranes into the walls of small vessels may be an epiphenomenon of the attacks.

Arteriosclerosis comprises elements of the vasculopathy described above and commonly affects the cerebral vasculature. Hyaline thickening of small vessels is particularly evident in hypertensive patients. The incorporation of platelet fragments into arteriosclerotic small vessels was not seen in the brains of our control patients.

The incorporation of platelets into atherosclerotic plaques is well recognised, but arteriosclerosis is a disease of large and medium sized arteries, rather than the small vessels affected in CNS SLE.

Cerebrovascular abnormalities dominate the neuropathology of SLE, but their precise association with symptomatology has yet to be determined. Exacerbations of CNS SLE correlate with reduced cerebral blood flow on single photon emission tomography, and with complement activation. Immune complex deposition and vasculitis associated with complement activation can be focal and short-lived, and may account for fluctuating neuropsychiatric symptoms. Antineuronal antibodies probably contribute to these phenomena, gaining access to the brain during a temporary breakdown in the blood-brain barrier consequent on vasculitis. Both the vasculitis itself and any residual vessel damage may produce infarction and permanent symptomatology.

Antiphospholipid antibodies are associated with cerebral infarction in patients with SLE, and some of these have an anti-
endothelial action which may be associated with hypofibrinolysis. Such autoimmune activity could be the setting for thrombus formation and transient focal ischaemia in small vessels. Focal ischaemia followed by reperfusion predisposes to platelet deposition along small vessels, and may facilitate the intramural incorporation of platelet derived material during resolution of the inflammatory process.

Antiphospholipid antibodies are also associated with Libman-Sacks endocarditis, and emboli from cardiac lesions may contribute to the cerebrovascular lesions. However, both the referenced pathological studies found no consistent association between cerebral lesions and endocarditis. Libman-Sacks endocarditis was found in only one of our cases (case 6; tables 1 and 2). However, its absence at necropsy in the other SLE patients does not discount a similar process at some time during their histories of CNS symptoms.

In conclusion, we have shown the intramural deposition of platelet derived material in small cerebral vessels in four cases of CNS SLE. This was not evident in two other cases where a history of CNS SLE was relatively short, and where thickening and eosinophilia of small vessels were not found. Intramural platelet deposition in association with vasculopathy may follow repeated episodes of inflammation. A similar process may occur in slightly larger vessels in polyarteritis nodosa. The phenomenon appears rather specific because it was not seen in a variety of other inflammatory conditions that affect the cerebral vasculature. However, further study of more cases would be needed to confirm this.

Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus.

D Ellison, K Gatter, A Heryet and M Esiri

doi: 10.1136/jcp.46.1.37

Updated information and services can be found at:
http://jcp.bmj.com/content/46/1/37

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:  
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:  
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:  
http://group.bmj.com/subscribe/